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Abstract 22 
Human cytomegalovirus (HCMV), a member of the herpesvirus family, can cause significant 23 
morbidity and mortality in immune compromised patients resulting from either primary lytic 24 
infection or reactivation from latency. Latent infection is associated with a restricted viral 25 
transcription programme compared to lytic infection which consists of defined protein coding RNAs 26 
but also includes a number of virally encoded microRNAs (miRNAs).  One of these, miR-UL112-1, is 27 
known to target the major lytic IE72 transcript but, to date, a functional role for miR-UL112-1 during 28 
latent infection has not been shown. To address this, we have analysed latent infection in myeloid 29 
cells using a virus in which the target site for miR-UL112-1 in the 3' untranslated region of IE72 was 30 
removed such that any IE72 RNA present during latent infection would no longer be subject to 31 
regulation by miR-UL112-1 through the RNAi pathway. Our data show that removal of the miR-32 
UL112-1 target site in IE72 results in increased levels of IE72 RNA in experimentally latent primary 33 
monocytes. Furthermore, this resulted in induction of IE expression detectable by IE-specific 34 
cytotoxic T cells (CTLs); no such CTL recognition of monocytes latently infected with wild-type virus 35 
was observed. We also recapitulated these findings in the more tractable THP-1 cell line model of 36 
latency. These observations argue that an important role for miR-UL112-1 during latency is to ensure 37 
tight control of lytic viral IE gene expression thereby preventing recognition of latently infected cells 38 
by the host's potent pre-existing anti-viral CTL response.  39 
Introduction 40 
Human cytomegalovirus (HCMV) is a species specific herpesvirus carried by 60-80% of human 41 
populations, depending upon demographics (Ross & Boppana, 2005). In the immune competent, 42 
primary infection rarely results in clinical problems. However, in the immune compromised and the 43 
neonate, primary HCMV infection can cause significant disease sequelae (Ho, 1990; Zaia, 1990).                                                                   44 
 
 
 Like all herpesviruses, HCMV is never cleared after primary infection but maintains a life-long 45 
persistence which is underpinned by the ability of the virus to undergo latent infection (Sinclair & 46 
Sissons, 2006). As with primary infection, reactivation of virus from latency in the immune 47 
compromised or during pregnancy, can also result in severe disease to the immunocompromised 48 
individual or the foetus in utero (Adler, 1983; Griffiths & Walter, 2005; Rubin, 1990; Sissons & 49 
Carmichael, 2002).  50 
One established site of latent carriage, in vivo, is in cells of the myeloid lineage, including CD14+ 51 
monocytes and their CD34+ progenitors (Hahn et al., 1998; Khaiboullina et al., 2004; Mendelson et 52 
al., 1996; Taylor-Wiedeman et al., 1991). However, differentiation of these cells to dendritic  cells 53 
(DCs) or macrophages results in full virus reactivation (Reeves et al., 2005c; Soderberg-Naucler et al., 54 
2001; Taylor-Wiedeman et al., 1994).  55 
During latent infection of monocytes or CD34+ cells, carriage of latent viral genomes is associated 56 
with the expression of a restricted pattern of viral genes compared to lytically infected cells 57 
(Slobedman et al., 2010); the absence of infectious virion production during this life cycle mitigates 58 
the need for expression of much of the virus genome and likely, in itself, reduces the ability of the 59 
host's immune response to detect and clear virus infected cells.  Instead, viral gene expression 60 
during latency is likely reduced to those that play an important role in establishment and 61 
maintenance of the latent life cycle, and functions for proteins encoded by many of these latency-62 
associated transcripts are now beginning to be elucidated (Keyes et al., 2012b; O'Connor & Murphy, 63 
2012; Poole et al., 2014; Poole et al., 2015; Tarrant-Elorza et al., 2014; Weekes et al., 2013). In 64 
addition to these, it is also becoming clear that known viral non-coding RNAs are also expressed 65 
during latency (Rossetto et al., 2013) and these include viral miRNAs (Fu et al., 2014; Meshesha et 66 
al., 2016; Shen et al., 2014). Although the functional targets of a number of viral miRNAs expressed 67 
during lytic infection have been described (for reviews see: Dhuruvasan et al., 2011; Goldberger & 68 
 
 
Mandelboim, 2014; Hook et al., 2014a) , little is known about the role of HCMV encoded miRNAs 69 
during latency.  70 
One viral miRNA expressed during latency in primary myeloid cells is miR-UL112-1 (Meshesha et al., 71 
2016) (Betty Lau et al unpublished observations).  A number of cellular and viral targets of this 72 
miRNA have been validated during lytic infection (Grey, 2015; Huang et al., 2013; Lee et al., 2012); 73 
these include multiple components of the host secretory pathway (Hook et al., 2014b), the NK cell 74 
activatory ligand MICB (Stern-Ginossar et al., 2008), cellular transcription factor BclAF1 (Lee et al., 75 
2012) as well as the viral IE72 immediate early gene and viral UL114 (Grey et al., 2007; Murphy et al., 76 
2008; Stern-Ginossar et al., 2009). Furthermore, the targeting of MICB and BclAF1 by miR-UL112-1 77 
was shown to aid immune evasion and virus spreading, respectively, during lytic infection (Lee et al., 78 
2012; Stern-Ginossar et al., 2008). Despite a relative wealth of information about the role of this 79 
viral miRNA during lytic infection, nothing is known about the role of miR-UL112-1 during latency.  80 
On the basis that miR-UL112-1 targets IE72 expression during lytic infection, we reasoned that an 81 
even more crucial role for this viral miRNA could be its ability to target IE72 during latent infection; 82 
thereby helping to ensure tight negative regulation of lytic gene expression, and hence virus 83 
production, during latent carriage - a known hallmark of latency.   84 
Here, we have analysed whether the ability of miR-UL112-1 to target IE72, specifically, is important 85 
for latent carriage. Since miR-UL112-1 is known to have other cellular targets (Hook et al., 2014b; 86 
Huang et al., 2013; Lee et al., 2012) besides viral IE72, we approached this by generating 87 
recombinant virus in which the miR-UL112-1 target site in the 3' untranslated region (UTR) of IE72 88 
was removed (Δ112-1 target virus) rather than by deleting the miR-UL112-1 miRNA coding sequence 89 
itself - so ensuring that any phenotype we observed during latency was a result of lack of targeting 90 
of IE72 by miR-UL112-1 rather than its other known or unknown targets. 91 
Our results show that, as expected, latent infection with wild-type virus result in very low levels of 92 
IE72 RNA expression. In contrast, latent infection with Δ112-1 target virus results in latently infected 93 
 
 
cells expressing substantial levels of IE72 RNA. Importantly, as opposed to cells latently infected with 94 
wild-type virus, cells latently infected with Δ112-1 target virus now become overt targets for IE72 95 
specific CD8+ cytotoxic T cells.  96 
Finally, the difficulty in using primary cells from healthy donors led us to interrogate whether cell 97 
line models of HCMV latency could be used for similar immunological analyses of HCMV latent 98 
infection. Using the THP-1 cell line model of latency, we have recapitulated our observations on the 99 
effects of latent infection in the absence of miR-UL112-1; as with primary cells, THP-1 cells latently 100 
infected with Δ112-1 target virus also become overt targets for IE72 specific CD8+ cytotoxic T cells.  101 
Taken together, our data define an important role for miR-UL112-1 in the maintenance of latency as 102 
well as demonstrating the applicability of the THP-1 model system for intricate analysis of HCMV 103 
latency at the molecular and immunological level. We believe that expression of miR-UL112-1 during 104 
latency is important to "mop up" leaky IE RNA expression to prevent recognition of latently infected 105 
cells by the robust IE72 specific CTL response known to be present in normal HCMV carriers 106 
(Gillespie et al., 2000; Kern et al., 1998).  107 
Results 108 
Deletion of the miR-UL112-1 target site in the IE72 3' UTR results in low level IE expression in primary 109 
monocytes but not full reactivation of virus production 110 
The viral miR-UL112-1 miRNA is expressed during latency in a number of experimental latent models 111 
including experimentally latent primary monocytes and CD34+ haemopoietic progenitor cells 112 
(Meshesha et al., 2016) (Betty Lau et al unpublished observations). Besides the documented ability 113 
of miR-UL112-1 to target IE72, this viral miRNA is also known to target cellular MICB (Stern-Ginossar 114 
et al., 2008),  multiple components of the host secretory pathway (Hook et al., 2014b), BclAF1 (Lee 115 
et al., 2012), IL-32 (Huang et al., 2013) and is likely to have other unidentified viral and cellular target 116 
RNAs as many biochemical analyses suggest that miRNAs may typically target dozens of targets. As 117 
 
 
we wanted to specifically address the effect of lack of IE72 RNA regulation by miR-UL112-1, without 118 
potential confounding effects of miR-UL112-1 on other targets, we decided to construct a 119 
recombinant virus (∆112-1 target) in which the miR-UL112-1 target binding site was removed (Fig. 120 
1a); so allowing an analysis of the effect of miR-UL112-1 on IE72 expression, in isolation.   121 
We initially analysed the establishment of latency after 4 days infection in CD14+ monocytes as we 122 
have done previously (Krishna et al., 2016; Weekes et al., 2013) with both wild- type (WT) or ∆112-1 123 
target virus which resulted in similar numbers of GFP+ latently infected cells (approximately 10-20%, 124 
data not shown) as well as similar levels of expression of the latency associated gene UL138 (Fig. 1b). 125 
However, the suppression of IE gene expression in comparison to levels of UL138 expression (which 126 
is a hallmark of latent infection), was only observed with the WT virus; perhaps not unexpectedly, 127 
cells latently infected with ∆112-1 target virus resulted in a discernible increase in levels of IE72 RNA 128 
(Fig. 1b).  Importantly, although cells latently infected with ∆112-1 target virus did show less 129 
suppressed IE72 expression, there was no evidence of virus production from these cells or, as 130 
expected, from cells latently infected with WT virus (Fig. 1c). Consistent with this, no late viral gene 131 
expression (pp28) was observed in cells latently infected with either virus (Fig. 1b). In contrast, 132 
reactivation of cells latently infected with WT or ∆112-1 target virus showed similar levels of viral 133 
gene IE and late gene expression (Fig. 1b) and both produced similar levels of infectious virions (Fig. 134 
1c).  135 
 136 
The expression of IE by cells otherwise latently infected with the miR-UL112-1 target mutant virus 137 
can be detected by IE specific T cells 138 
Given that cells latently infected with ∆112-1 target virus expressed detectable levels of IE72 RNA, 139 
we reasoned that, if translated, this would make these cells vulnerable to surveillance by the well 140 
characterized IE72-specific CD8+ cytotoxic T cell (CTL) response known to be present in the 141 
 
 
peripheral blood of many healthy HCMV carriers; up to 10% of all circulating CTLs in healthy virus 142 
carriers are IE72 specific (Gillespie et al., 2000; Kern et al., 1998). Consequently, we next tested 143 
whether cells latently infected with ∆112-1 target virus were differentially recognised by IE72-144 
specific CTLs compared to cells latently infected with WT virus.  145 
To do this, we generated a T cell line which recognised the previously mapped IE72 peptide VLE 146 
(Khan et al., 2002), presented by MHC Class I HLA-A2. Using Fluorospot analysis, we first checked 147 
that the T cell line  produced IFNγ when cultured with both peptide pulsed monocytes and DCs.   148 
These T cells were then used against latently infected monocyte targets as well as reactivating DC 149 
targets.  As expected, the T cell line recognised monocytes latently infected with WT or ∆112-1 150 
target virus which had been induced to reactivate by their differentiation to DCs (Fig. 2). In contrast, 151 
monocytes latently infected with WT virus showed little IE72 specific CTL recognition, whereas 152 
monocytes latently infected with ∆112-1 target virus were clearly recognised by IE-specific CTLs (Fig. 153 
2). Taken together, these data suggest that miR-UL112-1 is important for reinforcing the suppression 154 
of IE gene expression during latency to help prevent T cell recognition of latently infected cells by 155 
IE72-specific CTLs.  156 
Validation of the THP-1 cell model system 157 
All the analyses, so far, were carried out using latently infected primary human monocytes obtained 158 
from healthy blood donors; this requires local ethical approval and access to clinical services which 159 
are not always readily available. On this basis, we wanted to determine if the effects of a lack of the 160 
miR-UL112-1 target site on T cell surveillance could be recapitulated in other, more tractable, 161 
models of HCMV latency.  162 
A number of models of HCMV latency which use established myeloid cell lines have been described 163 
and these include myeloid cells expressing the CD34+ marker, such as Kasumi-3 (O'Connor & 164 
Murphy, 2012), or CD14+ monocytic cells, such as THP-1s (Keyes et al., 2012a), which can 165 
 
 
recapitulate many aspects of HCMV latency and reactivation observed in primary cells (Albright & 166 
Kalejta, 2013). The ability to use such established cell line model systems in the analysis of HCMV 167 
latency has a number of advantages which include their ease of use compared with primary cells, 168 
the lack of a requirement to recruit donors and, importantly, there would be no need to tissue type 169 
match each individual donor for e.g. immunological assays. Such cell lines are also homogenous and 170 
more easily to manipulate by e.g. transfection. 171 
As observed by others (Keyes et al., 2012a), THP-1 cells acted as a tractable model of latent 172 
infection. However, we found that growing cells in 2% FCS, rather than 10% FCS (as is standard), 173 
after infection reduced large scale expansion of the cell population and the associated loss of viral 174 
genomes (see Supplementary Fig. S1). Fig. 3a shows that latent infection of THP-1 cells resulted in 175 
cells which express good levels of viral UL138 RNA in a background of much reduced expression viral 176 
IE72 RNA, compared to levels of IE72 RNA expressed upon reactivation (e.g. see Fig. 3a, tracks 177 
labelled +PMA).  Consistent with this low level of IE72 RNA expression, we observed extremely low 178 
levels of IE72 protein expression using indirect immunofluorescence (Fig. 3b, left panel). In contrast, 179 
differentiation of these latently infected cells resulted in induction of IE72 expression at the level of 180 
RNA (Fig. 3a) and detection of numerous IE72 positive cells (Fig. 3b, right panel). Perhaps most 181 
importantly, on the basis that lack of infectious virus is a hallmark of latency, co-culture of the 182 
undifferentiated latently infected THP-1 cells (shown in the left panel of Fig. 3b) with fully permissive 183 
indicator fibroblasts showed no infectious virus production (Fig. 3c, left panel). In contrast, 184 
reactivated virus was clearly detectable (Fig. 3c, right panel) after co-culture of these differentiated 185 
latently infected THP-1 cells (shown in right panel, Fig. 3b) with indicator fibroblasts. Taken together, 186 
these data show that infection of THP-1 cells results in latent HCMV infection which can be 187 
reactivated by differentiation.  188 
 189 
 190 
 
 
THP-1 cells latently infected with ∆112-1 target virus also show de-repressed IE expression and 191 
become targets for IE-specific CTLs  192 
Fig. 2 clearly showed that removal of the miR-UL112-1 target site in IE72 prevented the repression of 193 
IE gene expression during HCMV latency in primary monocytes. Consequently, we tested whether 194 
latently infected THP-1 cells also showed the same effect. Fig. 4a shows that infection of THP-1 cells 195 
with both wild-type virus and ∆112-1 target virus resulted in equivalent levels of UL138 expression; 196 
this was not the case for expression of IE72.  Although infection with WT virus did result in some 197 
detectable levels of IE72 expression, consistent with the less robust control of expression of IE72 198 
known to occur upon latent infection of THP-1 cells (Keyes et al., 2012a) compared to monocytes, 199 
infection with ∆112-1 target virus resulted in substantially increased levels of IE72 RNA. This argues 200 
that, during latent infection of THP-1 cells, the ∆112-1 target virus is less able to suppress IE gene 201 
expression during latency in the absence of the miR-UL112-1 target site; exactly as observed for 202 
primary monocytes. 203 
In order for us to determine if THP-1 cells latently infected with ∆112-1 target virus were also more 204 
susceptible to surveillance by IE72-specific CTLs, we needed to determine whether THP-1 cells could 205 
act as targets for IE-specific T cells in an MHC Class I restricted manner. THP-1 cells are known to 206 
express high levels of HLA-A2 and, consequently, when loaded with the HLA-A2 restricted VLE 207 
polypeptide of IE72 should present and be recognised by VLE-specific CTLs (Khan et al., 2002). Fig. 5a 208 
shows that, as expected, THP-1 cells express high levels of HLA-A2 and, when pulsed with a VLE 209 
polypeptide, are recognised in a dose dependent manner by a VLE-specific CTL line using 210 
IFNϒELISpot analysis (Fig. 5b). Given that THP-1 cells can act as IE-specific CTL targets in this setting, 211 
we next tested whether these IE-specific T cells recognised latently infected THP-1 cells, lytically 212 
infected differentiated THP-1 cells or latently infected THP-1 induced to reactivate by differentiation.  213 
Fig. 5c shows that differentiated THP-1 cells infected with HCMV, which undergo lytic infection, are 214 
recognised by IE-specific CTLs, as expected. In contrast, THP-1 cells latently infected with HCMV are 215 
 
 
poorly recognised by VLE-specific CTLs but do become targets when these latently infected cells are 216 
induced to reactivate.  This is consistent with the targeting of infected THP-1 by IE72-specific T cells 217 
only occurring when IE is fully expressed i.e. during lytic infection and reactivation, but not latency.   218 
Finally, we analysed whether THP-1 cells latently infected with ∆112-1 target virus were also targets 219 
for IE-specific CTLs, as we had observed using primary monocytes. To do this, we analysed the ability 220 
of IE-specific CTLs to reduce the number of GFP-tagged latently infected cells after latent infection 221 
with WT or ∆112-1 target virus. Fig. 5d shows that, as expected, irrelevant EBV-specific T cells had no 222 
effect on the number of GFP-tagged latently infected THP-1 cells regardless of whether latency was 223 
established with WT or ∆112-1 target virus. In contrast, if IE-specific CTLs were used in the assay, the 224 
number of GFP-tagged latently infected THP-1 cells was reduced almost three fold when latency was 225 
established using ∆112-1 target virus compared to cells latently infected with WT virus. 226 
Formally, whilst it is possible that this removal of these otherwise latently infected THP-1 cells 227 
expressing IE antigen results from CTL-mediated repression of IE gene expression and that these 228 
THP-1 cells still carry reactivatable virus, we think this unlikely as cells which are induced to 229 
transiently express IE72 by treatment of latently infected cells with histone deacetylase inhibitors 230 
(HDACi) are killed by IE-specific CTLs (Krishna et al., 2016). 231 
Collectively, these data show THP-1 cells is a tractable experimental model of latency in which we 232 
were able to reproduce the observations with regards to the downregulation of IE72 by miR-UL112-1 233 
during latency.   234 
 235 
Discussion 236 
The inability of HCMV latently infected cells to be cleared by the host after primary infection, even 237 
though host T cell responses to HCMV are profound and long-term, argues that latent reservoirs are 238 
unable to be surveilled and targeted by the extremely large HCMV-specific CD8+ and CD4+ T cell 239 
 
 
response known to be present in normal healthy HCMV carriers (Wills et al., 2015). Indeed, up to 240 
10% of the CD8+ T cell compartment in peripheral blood of some healthy HCMV seropositive carriers 241 
recognise IE72 antigen (Gillespie et al., 2000; Kern et al., 1998). Consequently, robust repression of 242 
IE72 expression during latent carriage is likely to be of critical importance in order to prevent latently 243 
infected cells from being recognised and cleared by the well established IE72-specific anti-viral T cell 244 
response. 245 
We and others have shown that latent infection of both experimentally and naturally latent myeloid 246 
lineage cells results in a latency-associated transcription programme in which IE gene expression is 247 
profoundly suppressed; this results from repression of the viral major immediate early promoter 248 
(MIEP) mediated by concerted actions of cellular transcriptional suppressor proteins (Murphy et al., 249 
2002; Rauwel et al., 2015; Reeves et al., 2005c) and viral regulators of IE expression (Lee et al., 2015) 250 
reflected in repressive histone post-translational modifications around the MIEP (Murphy et al., 251 
2002; Reeves et al., 2005b; Reeves et al., 2005c). Our view is that, as with transcription in general, 252 
such repression is likely to be leaky, resulting in incomplete silencing of IE gene expression and, 253 
hence, requiring additional levels of IE suppression. The viral miR-UL112-1 miRNA has been shown to 254 
attenuate IE72 expression during lytic infection at low multiplicities of infection (Grey et al., 2007; 255 
Murphy et al., 2008). This led us to analyse the role of miR-UL112-1 during latent infection when, we 256 
predict, such fine tuning of IE72 expression may be particularly important. Consistent with this, 257 
experimental latent infection of CD14+ monocytes with the ∆112-1 target virus consistently resulted 258 
in a significant increase in IE72 RNA compared to latency established with WT virus. Despite this, the 259 
increase in IE72 RNA in cells latently infected with ∆112-1 target did not result in virus reactivation 260 
as determined by virus co-culture analysis. It did, however, result in the ability of these cells latently 261 
infected with ∆112-1 target virus to be detected by IE72 specific CTLs, resulting in their killing; again, 262 
no such killing of cells latently infected with WT virus was observed. 263 
 
 
We also addressed whether we could recapitulate these findings in an established cell line model of 264 
HCMV latency, as there are a number of advantages associated with using such cell lines over 265 
primary cells for HCMV latency studies; their ease of use, the lack of requirement for ethical 266 
approval, the ability to manipulate them by e.g. transfection as well as their homogeneity as a cell 267 
population. Using these cells, we are able to recapitulate our key observations using primary 268 
monocytes and, therefore, believe that the THP-1 latency model represents a tractable model for 269 
also addressing immune control of HCMV latency and reactivation. 270 
Taken together, we posit that miR-UL112-1 has a key role during latency which is to ensure robust 271 
control of expression of viral IE72 by minimising translation of any low levels of IE72 transcription 272 
which escapes latency-associated repression of the MIEP; if left uncontrolled, expression of this lytic 273 
antigen would otherwise result in latently infected cells becoming targets for the robust IE72 274 
antiviral response routinely observed in healthy HCMV carriers. 275 
 276 
Materials and Methods 277 
Cells and viruses 278 
For latent infections, primary monocytes were isolated from venous blood of an HLA-A2 HCMV 279 
seronegative donor by CD14+ MACS microbeads positive selection (Miltenyi Biotec) as instructed by 280 
the manufacturer. Briefly, peripheral blood mononuclear cells were extracted from venous blood by 281 
Lymphoprep density gradient centrifugation (Axis-Shield), as previously described (Mason et al., 282 
2013). PBMCs were then incubated with CD14 direct microbeads before application of a magnetized 283 
LS column, and subsequently eluting the bound cells after washing the column. The purity of isolated 284 
cells were analysed by flow cytometry which routinely showed 98.1% cells expressed CD14 (range 285 
97.4–98.9%). Primary monocytes were cultured in X-Vivo-15 (Lonza) supplemented with 2.5mM L-286 
glutamine (GE healthcare). 287 
 
 
THP-1 cells (TIB-202, ATCC) were propagated in RPMI (Lonza) supplemented with 10% heat-288 
inactivated fetal calf serum (FCS, F7524, Sigma-Aldrich) and 0.04% gentamicin (Gibco – Life 289 
Technologies). During latency and reactivation experiments, THP-1 cells were cultured in RPMI 290 
supplemented with 2% FCS. 291 
ARPE-19 cells (CRL-2302, ATCC) and neonatal NHDF fibroblasts (CC-2509, Lonza) were grown 292 
respectively in DMEM:F12 with L-glutamine (733-1713, Biowhittaker) and MEM (11095-098, Gibco – 293 
Life Technologies) containing 10% FCS and 0.04% gentamicine. Stocks of HCMV TB40/E (Chou & 294 
Scott, 1988) were generated on ARPE-19 to obtain highly endothelial tropic virus. Virus yield was 295 
determined by an immune-fluorescence assay adapted from Chou et al. (Chou & Scott, 1988). After 296 
scoring, the virus titre (TCID50/ml) was calculated based on the Spearman-Kärber method.  297 
TB40E-GFP ∆112-1 target virus was derived from TB40E-eGFP (O'Connor & Murphy, 2012), based on 298 
the HCMV bacterial artificial chromosome (BAC)-derived strain TB40/E (clone 4) and which was 299 
previously engineered to express enhanced green fluorescent protein (eGFP). TB40-eGFP was used 300 
as the wild-type virus where indicated and was used to generate the TB40/Egfp Δ112-1 mutant using 301 
galK BAC recombineering protocols. The TB40/Egfp Δ112-1 mutant contains 12 single base pair 302 
substitutions that abrogate expression of miR-112-1, while maintaining the coding potential of the 303 
UL114 ORF located on the opposite strand. Mutagenesis was performed on the BAC clone of 304 
TB40/Egfp, using the galK selection and counter selection recombineering protocols as previously 305 
described (Warming et al., 2005). Briefly, the TB40/Egfp-BAC was transformed into E. coli SW102, 306 
which has the heat inducible recombination genes required for BAC-mediated recombineering. PCR 307 
products were generated with primers that contain 50 bases pairs of HCMV flanking sequence 308 
targeting recombination of the galK expression cassette to the location of interest. The forward and 309 
reverse primers to insert galK into the miR-UL112-1 sequence were 5’- 310 
GGCGCTCTGACAGCCTCCGGATCACATGGTTACTCAGCGTCTGCCAGCCcctgttgacaattaatcatcggcga-3’ and 311 
5’-GCGACGCGGCGTGCTGCTGCTCAACACCGTGTTCACCGTGGTGCACGGACtcagcactgtcctgctcctt-3’, 312 
 
 
respectively (capitalized nucleotides correspond to the HCMV sequence). TB40-eGFP-BAC-containing 313 
SW102 cells were made competent and transformed with the HCMV flanking galK PCR product. 314 
Transformed cells were plated on M63 minimal salt agar plates supplemented with chloramphenicol 315 
(12.5 μg/ml) and 0.2% galactose. TB40- eGFP-BAC clones that underwent homologous 316 
recombination were additionally screened for growth on McConkey's medium supplemented with 317 
galactose. Positive colonies (red) were picked and further screened by PCR to confirm the proper 318 
location of the galK insert. Positive colonies were made electrocompetent and transformed with 80-319 
base pair double-stranded DNA with HCMV sequences that flank the galK integrated sequence 320 
surrounding the sequence to be substituted into the viral genome. The double-stranded DNA used 321 
to mutate the mature miRNA sequence of miR-UL112-1 was generated by annealing the following 322 
oligonucleotides: 5’-323 
GTGCTGCTGCTCAACACCGTGTTCACCGTGGTGCACGGACAACCCGGGAGCCATAGGCATCTGGGCTGGCAG324 
ACGCTGAGTAACCATGTGATCCGGAGGCTG-3’ and 5’-325 
CAGCCTCCGGATCACATGGTTACTCAGCGTCTGCCAGCCCAGATGCCTATGGCTCCCGGGTTGTCCGTGCACC326 
ACGGTGAACACGGTGTTGAGCAGCAGCAC -3’.Positive recombinants are selected by growth on m63 327 
minimal salt agar plates containing 0.2% 2-deoxy-galactose (2-DOG) and 0.2% glucose. All mutations 328 
were validated by sequencing the recombinant viruses. Virus was generated by electroporation of 329 
primary fibroblasts with BAC DNA (20 μg) plus an HCMV pp71-expressing plasmid (pCGNpp71). After 330 
a 100% cytopathic effect was achieved, virus was harvested by ultracentrifugation through a 20% 331 
sorbitol cushion. Viral pellets were resuspended in X-VIVO 15 medium (Lonza) supplemented with 332 
1.5% bovine serum albumin. Aliquots were flash frozen in liquid nitrogen and stored at −80°C until 333 
further use. Stock titers were assessed by 50% tissue culture infective dose assays on primary 334 
fibroblasts.  335 
THP-1 latency and reactivation model 336 
 
 
Twenty four hours prior to infection, THP-1 cells were pre-incubated in RPMI with 2% heat-337 
inactivated FCS (RPMI/2% FCS). This reduced large scale expansion of the cell population and the 338 
associated loss of viral genomes (see Supplementary Fig. S1). To obtain latently infected cells, 339 
undifferentiated THP-1 cells were infected at MOI 5 with HCMV for 3-4 hours at 37°C in 0.5ml 340 
RPMI/2% FCS per 6x105 cells with occasional agitation to avoid settling. After infection, the cells 341 
were washed once with 2ml RPMI/2% FCS and spun down at 300g (5 minutes).  The cells were 342 
resuspended in RPMI/2% FCS, plated in a 24-well plate and incubated for 3 days at 37°C/5% CO2. To 343 
induce reactivation, the cells were differentiated to THP-1 macrophages using 100nM phorbol 12-344 
myristate 13-acetate (PMA, Sigma-Aldrich).  345 
A similar protocol was used for immunological assays with small adaptations. After the 346 
establishment of latency (72 hours post infection), the medium was replaced by fresh medium and 347 
24 hours later cells were used as stimulator cells in IFNγ ELISPOT assays and in T cell co-culture 348 
experiments (see below). To obtain reactivated cells for IFNγ ELISPOT assays, latently infected cells 349 
were treated with PMA as described above and incubated for 96 hours. As controls, lytically infected 350 
cells were obtained by pre-treatment with PMA (100nM) for 48 hours. Subsequently, the THP-1 351 
macrophages were infected with TB40/E virus at MOI 5, incubated for a further 96 hours and then 352 
used as stimulator cells in IFNγ ELISPOT assays. 353 
Immediate-early antigen immunofluorescence assay 354 
On the day of read-out, undifferentiated THP-1 cells in suspension were collected by centrifugation 355 
at 300g for 5 minutes. The cells were washed once with PBS, resuspended in 200µl PBS and adhered 356 
to a glass adhesion slide (0901000, Mariënfeld Laboratory Glassware) as described by the 357 
manufacturer. Differentiated adherent THP-1 cells were stained directly in the 24-well plate. 358 
Fixation of the cells was carried out with 100% ice-cold methanol (10 minutes at -20°C). The slides or 359 
dishes were washed twice with PBS and incubated for 20 minutes at RT with anti-immediate-early 360 
 
 
antigen antibody (11-003, Argene) diluted 1/100 in PBST (PBS containing 0.05% tween-20). Before 361 
adding the secondary antibody (1/100, Alexa Fluor 488 goat anti-mouse IgG, A-11001, Life 362 
Technologies), the slides or dishes were washed twice with PBS. After 20 minutes of incubation with 363 
the secondary antibody, the cells were washed once with PBS. Positive cells were manually counted 364 
under an Axiovision fluorescence microscope. 365 
Fluorescent images were taken using an Axiovision fluorescence microscope (Bright field: 5-9 366 
milliseconds exposure; pseudo colour green fluorescence at laser intensity 25%: 500 milliseconds 367 
exposure). Overlays were made automatically using the Axiovision software. 368 
Analysis of viral RNA and DNA 369 
DNA and RNA samples were prepared from monocytes obtained from one well or three wells, 370 
respectively, of a 24-well plate. Non-adherent cells were collected by centrifugation (5 minutes, 371 
300g) to remove the medium and were subsequently washed once with PBS. The cells were 372 
collected again by centrifugation (300g, 5 minutes) and lysed in 500µl lysis buffer (Invisorb® Spin Cell 373 
Mini Kit) or 600µl RLT Plus buffer (Qiagen RNeasy Plus kit) to obtain DNA and RNA samples, 374 
respectively. After removing the medium, adherent cells were washed and lysed in the well. DNA 375 
was prepared according to the manufacturer’s instructions. RNA samples were prepared using a 376 
Qiagen RNeasy Plus kit with an additional on-column DNase digestion step according to the 377 
manufacturer’s instructions.  378 
Reverse transcription was carried out with oligo-dTs using the Superscript III kit (both from Life 379 
Technologies) according to the manufacturer’s instructions with an RNA input of 250-500ng. Gene 380 
specific primers were used to amplify GAPDH, IE1/UL123 and UL138 by PCR using the Expand High 381 
Fidelity PCR system (Roche) with the following cycling conditions: 95°C (5 minutes), 30 cycles of 94°C 382 
(40 seconds), 55°C (40 seconds), and 72°C (60 seconds), and a final extension at 72°C for 5 minutes 383 
 
 
(for primers see Table 1). PCR products were analyzed using agarose gel electrophoresis (2% E-gel, 384 
Life Technologies). Images were taken using an ImageQuant LAS 4000.  385 
RT-qPCR analyses were performed using the QuantiTect virus kit (Qiagen) as the manufactuer 386 
describes, using primers and probes listed in Table 1. The reaction mixtures consisted of 1x 387 
QuantiTect Virus NR Master Mix, 1x ROX Dye solution, 0.4µM of each forward and reverse primer, 388 
0.2µM probe, 1x QuantiTect Virus RT Mix and 20-50ng sample RNA. The RT-qPCRs were performed 389 
on 7500 Real-Time PCR System (Applied Biosystems) with cycling conditions as follows; 20 minutes 390 
at 50⁰C, 5 minutes at 95⁰C, then 50 cycles of 15 seconds at 95⁰C, 45 seconds at 60⁰C. All qPCR 391 
reactions were performed in duplicate with minus template controls and minus reverse 392 
transcriptase controls. Viral transcript levels were normalised to the housekeeping transcript 393 
GAPDH. The sensitivities of the qPCRs for UL138 and IE1/UL123 were approximately equivalent with 394 
both having a detection limit of about 10 copies of HCMV genome (Betty Lau, unpublished 395 
observations). In contrast, the conventional RT-PCRs with products detected by agarose gel 396 
electrophoresis were not quantitative and detect UL138 more efficiently than IE72 (Emma Poole, 397 
data not shown). 398 
Preparation of peripheral blood mononuclear cells (PBMC) 399 
Venous blood was obtained from a HLA-A2 HCMV seropositive individual and collected in sterile 400 
50ml tubes containing 4ml heparin sodium (100IU/ml) in PBS. The blood was diluted 1:2 with RPMI-401 
1640 containing no serum (PAA laboratories, Austria) supplemented with 105IU/ml penicillin, 402 
100mg/ml streptomycin, and 2mM L-glutamine. PBMC were isolated by Ficoll-Hypaque density 403 
gradient centrifugation, 25ml blood was layered onto 12.5ml Lymphoprep (Axis-Shield, Norway) and 404 
centrifuged at 800g for 15 minutes without the brake. PBMC were washed twice in PBS and 405 
resuspended in RPMI supplemented with 10% FCS (RPMI-10). Autologous serum was also collected 406 
and incubated 56°C for 30 minutes in a water bath to inactivate complement. Post incubation the 407 
serum was UV-irradiated for 30 minutes and aliquoted for freezing at -20°C. 408 
 
 
Expansion of HCMV specific CD8+ T-cells 409 
CD8+ T-cells were isolated from the PBMCs of an HLA-A2 HCMV seropositive individual using a 410 
magnetic CD8+ T-cell enrichment kit (StemCell technologies) and then resuspended in RPMI 411 
containing 10% FCS (Invitrogen) and 10% heat inactivated autologous donor serum. Cells were 412 
stimulated with irradiated autologous PBMC which had been pulsed with HCMV IE72 peptide VLE 413 
(Khan et al., 2002) or EBV specific GLC peptide (Steven et al., 1996). T cell cultures were carried out 414 
in the presence of 2.5IU/ml human recombinant IL-2 (National Institute for Biological Standards and 415 
Control, Potters Bar, United Kingdom) in 96-well plates at 37°C and a humidified CO2 atmosphere for 416 
10 – 14 days with feeding of the culture with the same media every five days. The specificity of 417 
expanded CD8+ cultures for mapped peptides was assessed by VLE HLA A2 specific pentamer 418 
staining. Briefly, cells were harvested and washed and then stained with the specific unlabelled 419 
pentamer (ProImmune), washed and then further stained with pentamer specific PE fluorophore 420 
(ProImmune) and CD8 and CD3 antibodies conjugated to PerCP-Cy5.5 and FITC, respectively. After 421 
this, cells were fixed and acquired on a FACS Sort using CellQuest software (BD Biosciences). Data 422 
was analyzed using FlowJo software. All expanded cell lines were tested for specificity using IFNγ 423 
ELISpot or Flourospot assays against THP-1 cells, monocytes and DCs. Antigen specific CD8+ T cells 424 
were frozen in Liquid Nitrogen at 2 X 106 cells/ml.  425 
Detection of cytokine production by ELISPOT and Fluorospot 426 
Human IFNγ ELISPOT (Ready-SET-Go!, eBioscience, San Diego, USA) assays were preformed 427 
according to the manufacturer’s instructions using 96-well PVDF membrane plates (Millipore, 428 
Billerica, USA). VLE specific CD8+ T-cells were rapidly defrosted at 37°C and diluted into 25mls of 429 
warm RPMI-10 washed once and incubated at 37oC for 2hrs before being counted and then added 430 
to wells at 12.5K, 25K or 50K T-cells per well in triplicate. The T-cells were stimulated with 50K THP-1 431 
cells that had been latently or lytically infected with HCMV or latently infected cells that had been 432 
 
 
reactivated. Positive controls were THP-1 cells pulsed with cognate peptide and negative controls 433 
were unpulsed and uninfected THP-1 cells.  434 
Plates were incubated for 48 hours at 37°C and then developed according to manufacturer’s 435 
instruction. Images of each well were taken using an ELISPOT plate scanner (ELISPOT Reader System, 436 
AID) and spots enumerated using ImageJ (National Institutes of Health). 437 
Human IFNγ Fluorospot plate (Mabtech AB, Nacka Strand, Sweden) assays were preformed 438 
according to the manufacturer’s instructions. Monocytes from an HLA-A2 HCMV seronegative donor 439 
were latently infected for 6 days with WT or ∆112-1 target virus and then left untreated or treated 440 
with IL-4/GM-CSF for an additional 6 days and then matured with LPS for 1 days to reactivate latent 441 
virus. These were then cocultured with and HLA-A2 restricted VLE specific CD8+ T-cells at 37ºC in a 442 
humidified CO2 atmosphere for 48 hours. The cells and medium were decanted from the plate and 443 
the assay developed following the manufacturer’s instructions.  Developed plates were read using 444 
an AID iSpot reader (AID) and counted using AID EliSpot v7 software.  445 
 446 
THP-1 co-culture 447 
THP-1 cells were plated at 5 x 104 cells per well in 48 well plates. At 3 days post infection, VLE or EBV 448 
(GLC) specific CD8+ T-cells were rapidly defrosted at 37oC and diluted into 25mls of warm RPMI-10 449 
washed once and incubated at 37°C for 2hrs before being counted and then added at the 450 
effector:target ratio of 3:4.  The numbers of GFP expressing cells across entire wells were 451 
enumerated 24 hours later. 452 
Ethical approval 453 
All human samples were obtained under ethical approval and after approval of protocols from the 454 
Cambridgeshire 2 Research Ethics Committee (REC reference 97/092) and these protocols were 455 
 
 
conducted in accordance with the Declaration of Helsinki. Informed written consent was obtained 456 
from all of the volunteers included in this study prior to providing blood samples and all experiments 457 
were carried out in accordance with the approved guidelines. 458 
 459 
Acknowledgements 460 
We gratefully acknowledge funding from the UK Medical Research Council (J.H.S. and M. R. W. 461 
G:0701279) which supports the current research in our laboratory and also the support of NIHR UK 462 
Biomedical Research Centre (J.H.S. and M. R. W.). 463 
 464 
References 465 
Adler, S. P. (1983). Transfusion-associated cytomegalovirus infections. Rev Infect Dis 5, 977-993. 466 
Albright, E. R. & Kalejta, R. F. (2013). Myeloblastic cell lines mimic some but not all aspects of 467 
human cytomegalovirus experimental latency defined in primary CD34+ cell populations. J 468 
Virol 87, 9802-9812. 469 
Chou, S. W. & Scott, K. M. (1988). Rapid quantitation of cytomegalovirus and assay of neutralizing 470 
antibody by using monoclonal antibody to the major immediate-early viral protein. J Clin 471 
Microbiol 26, 504-507. 472 
Dhuruvasan, K., Sivasubramanian, G. & Pellett, P. E. (2011). Roles of host and viral microRNAs in 473 
human cytomegalovirus biology. Virus Res 157, 180-192. 474 
Fu, M., Gao, Y., Zhou, Q., Zhang, Q., Peng, Y., Tian, K., Wang, J. & Zheng, X. (2014). Human 475 
cytomegalovirus latent infection alters the expression of cellular and viral microRNA. Gene 476 
536, 272-278. 477 
Gillespie, G. M., Wills, M. R., Appay, V., O'Callaghan, C., Murphy, M., Smith, N., Sissons, P., 478 
Rowland-Jones, S., Bell, J. I. & Moss, P. A. (2000). Functional heterogeneity and high 479 
frequencies of cytomegalovirus-specific CD8(+) T lymphocytes in healthy seropositive 480 
donors. J Virol 74, 8140-8150. 481 
Goldberger, T. & Mandelboim, O. (2014). The use of microRNA by human viruses: lessons from NK 482 
cells and HCMV infection. Seminars in immunopathology 36, 659-674. 483 
 
 
Goodrum, F., Reeves, M., Sinclair, J., High, K. & Shenk, T. (2007). Human cytomegalovirus 484 
sequences expressed in latently infected individuals promote a latent infection in vitro. 485 
Blood 110, 937-945. 486 
Grey, F. (2015). Role of microRNAs in herpesvirus latency and persistence. J Gen Virol 96, 739-751. 487 
Grey, F., Meyers, H., White, E. A., Spector, D. H. & Nelson, J. (2007). A human cytomegalovirus-488 
encoded microRNA regulates expression of multiple viral genes involved in replication. PLoS 489 
Pathog 3, e163. 490 
Griffiths, P. D. & Walter, S. (2005). Cytomegalovirus. Curr Opin Infect Dis 18, 241-245. 491 
Hahn, G., Jores, R. & Mocarski, E. S. (1998). Cytomegalovirus remains latent in a common precursor 492 
of dendritic and myeloid cells. Proc Natl Acad Sci U S A 95, 3937-3942. 493 
Ho, M. (1990). Epidemiology of cytomegalovirus infections. Rev Infect Dis 12 Suppl 7, S701-710. 494 
Hook, L., Hancock, M., Landais, I., Grabski, R., Britt, W. & Nelson, J. A. (2014a). Cytomegalovirus 495 
microRNAs. Curr Opin Virol 7, 40-46. 496 
Hook, L. M., Grey, F., Grabski, R., Tirabassi, R., Doyle, T., Hancock, M., Landais, I., Jeng, S., 497 
McWeeney, S., Britt, W. & Nelson, J. A. (2014b). Cytomegalovirus miRNAs target secretory 498 
pathway genes to facilitate formation of the virion assembly compartment and reduce 499 
cytokine secretion. Cell Host Microbe 15, 363-373. 500 
Huang, Y., Qi, Y., Ma, Y., He, R., Ji, Y., Sun, Z. & Ruan, Q. (2013). The expression of interleukin-32 is 501 
activated by human cytomegalovirus infection and down regulated by hcmv-miR-UL112-1. 502 
Virology journal 10, 51. 503 
Kern, F., Surel, I. P., Brock, C., Freistedt, B., Radtke, H., Scheffold, A., Blasczyk, R., Reinke, P., 504 
Schneider-Mergener, J., Radbruch, A., Walden, P. & Volk, H. D. (1998). T-cell epitope 505 
mapping by flow cytometry. Nat Med 4, 975-978. 506 
Keyes, L. R., Bego, M. G., Soland, M. & St Jeor, S. (2012a). Cyclophilin A is required for efficient 507 
human cytomegalovirus DNA replication and reactivation. J Gen Virol 93, 722-732. 508 
Keyes, L. R., Hargett, D., Soland, M., Bego, M. G., Rossetto, C. C., Almeida-Porada, G. & St Jeor, S. 509 
(2012b). HCMV protein LUNA is required for viral reactivation from latently infected primary 510 
CD14(+) cells. PLoS One 7, e52827. 511 
Khaiboullina, S. F., Maciejewski, J. P., Crapnell, K., Spallone, P. A., Dean Stock, A., Pari, G. S., 512 
Zanjani, E. D. & Jeor, S. S. (2004). Human cytomegalovirus persists in myeloid progenitors 513 
and is passed to the myeloid progeny in a latent form. Br J Haematol 126, 410-417. 514 
Khan, N., Cobbold, M., Keenan, R. & Moss, P. A. (2002). Comparative analysis of CD8+ T cell 515 
responses against human cytomegalovirus proteins pp65 and immediate early 1 shows 516 
 
 
similarities in precursor frequency, oligoclonality, and phenotype. J Infect Dis 185, 1025-517 
1034. 518 
Krishna, B. A., Lau, B., Jackson, S. E., Wills, M. R., Sinclair, J. H. & Poole, E. (2016). Transient 519 
activation of human cytomegalovirus lytic gene expression during latency allows cytotoxic T 520 
cell killing of latently infected cells. Sci Rep 6, 24674. 521 
Lee, S. H., Albright, E. R., Lee, J. H., Jacobs, D. & Kalejta, R. F. (2015). Cellular defense against latent 522 
colonization foiled by human cytomegalovirus UL138 protein. Sci Adv 1, e1501164. 523 
Lee, S. H., Kalejta, R. F., Kerry, J., Semmes, O. J., O'Connor, C. M., Khan, Z., Garcia, B. A., Shenk, T. 524 
& Murphy, E. (2012). BclAF1 restriction factor is neutralized by proteasomal degradation 525 
and microRNA repression during human cytomegalovirus infection. Proc Natl Acad Sci U S A 526 
109, 9575-9580. 527 
Mason, G. M., Jackson, S., Okecha, G., Poole, E., Sissons, J. G., Sinclair, J. & Wills, M. R. (2013). 528 
Human cytomegalovirus latency-associated proteins elicit immune-suppressive IL-10 529 
producing CD4(+) T cells. PLoS Pathog 9, e1003635. 530 
Mendelson, M., Monard, S., Sissons, P. & Sinclair, J. (1996). Detection of endogenous human 531 
cytomegalovirus in CD34+ bone marrow progenitors. J Gen Virol 77 ( Pt 12), 3099-3102. 532 
Meshesha, M. K., Bentwich, Z., Solomon, S. A. & Avni, Y. S. (2016). In vivo expression of human 533 
cytomegalovirus (HCMV) microRNAs during latency. Gene 575, 101-107. 534 
Murphy, E., Vanicek, J., Robins, H., Shenk, T. & Levine, A. J. (2008). Suppression of immediate-early 535 
viral gene expression by herpesvirus-coded microRNAs: implications for latency. Proc Natl 536 
Acad Sci U S A 105, 5453-5458. 537 
Murphy, J. C., Fischle, W., Verdin, E. & Sinclair, J. H. (2002). Control of cytomegalovirus lytic gene 538 
expression by histone acetylation. Embo j 21, 1112-1120. 539 
O'Connor, C. M. & Murphy, E. A. (2012). A myeloid progenitor cell line capable of supporting human 540 
cytomegalovirus latency and reactivation, resulting in infectious progeny. J Virol 86, 9854-541 
9865. 542 
Poole, E., Avdic, S., Hodkinson, J., Jackson, S., Wills, M., Slobedman, B. & Sinclair, J. (2014). 543 
Latency-associated viral interleukin-10 (IL-10) encoded by human cytomegalovirus 544 
modulates cellular IL-10 and CCL8 Secretion during latent infection through changes in the 545 
cellular microRNA hsa-miR-92a. J Virol 88, 13947-13955. 546 
Poole, E., Lau, J. C. & Sinclair, J. (2015). Latent infection of myeloid progenitors by human 547 
cytomegalovirus protects cells from FAS-mediated apoptosis through the cellular IL-10/PEA-548 
15 pathway. J Gen Virol 96, 2355-2359. 549 
 
 
Rauwel, B., Jang, S. M., Cassano, M., Kapopoulou, A., Barde, I. & Trono, D. (2015). Release of 550 
human cytomegalovirus from latency by a KAP1/TRIM28 phosphorylation switch. Elife 4. 551 
Reeves, M., Sissons, P. & Sinclair, J. (2005a). Reactivation of human cytomegalovirus in dendritic 552 
cells. Discov Med 5, 170-174. 553 
Reeves, M. B., Lehner, P. J., Sissons, J. G. & Sinclair, J. H. (2005b). An in vitro model for the 554 
regulation of human cytomegalovirus latency and reactivation in dendritic cells by chromatin 555 
remodelling. J Gen Virol 86, 2949-2954. 556 
Reeves, M. B., MacAry, P. A., Lehner, P. J., Sissons, J. G. & Sinclair, J. H. (2005c). Latency, chromatin 557 
remodeling, and reactivation of human cytomegalovirus in the dendritic cells of healthy 558 
carriers. Proc Natl Acad Sci U S A 102, 4140-4145. 559 
Ross, S. A. & Boppana, S. B. (2005). Congenital cytomegalovirus infection: outcome and diagnosis. 560 
Semin Pediatr Infect Dis 16, 44-49. 561 
Rossetto, C. C., Tarrant-Elorza, M. & Pari, G. S. (2013). Cis and trans acting factors involved in 562 
human cytomegalovirus experimental and natural latent infection of CD14 (+) monocytes 563 
and CD34 (+) cells. PLoS Pathog 9, e1003366. 564 
Rubin, R. H. (1990). Impact of cytomegalovirus infection on organ transplant recipients. Rev Infect 565 
Dis 12 Suppl 7, S754-766. 566 
Shen, Z. Z., Pan, X., Miao, L. F., Ye, H. Q., Chavanas, S., Davrinche, C., McVoy, M. & Luo, M. H. 567 
(2014). Comprehensive analysis of human cytomegalovirus microRNA expression during lytic 568 
and quiescent infection. PLoS One 9, e88531. 569 
Sinclair, J. & Sissons, P. (2006). Latency and reactivation of human cytomegalovirus. J Gen Virol 87, 570 
1763-1779. 571 
Sissons, J. G. & Carmichael, A. J. (2002). Clinical aspects and management of cytomegalovirus 572 
infection. J Infect 44, 78-83. 573 
Slobedman, B., Cao, J. Z., Avdic, S., Webster, B., McAllery, S., Cheung, A. K., Tan, J. C. & Abendroth, 574 
A. (2010). Human cytomegalovirus latent infection and associated viral gene expression. 575 
Future Microbiol 5, 883-900. 576 
Soderberg-Naucler, C., Streblow, D. N., Fish, K. N., Allan-Yorke, J., Smith, P. P. & Nelson, J. A. 577 
(2001). Reactivation of latent human cytomegalovirus in CD14(+) monocytes is 578 
differentiation dependent. J Virol 75, 7543-7554. 579 
Stern-Ginossar, N., Gur, C., Biton, M., Horwitz, E., Elboim, M., Stanietsky, N., Mandelboim, M. & 580 
Mandelboim, O. (2008). Human microRNAs regulate stress-induced immune responses 581 
mediated by the receptor NKG2D. Nat Immunol 9, 1065-1073. 582 
 
 
Stern-Ginossar, N., Saleh, N., Goldberg, M. D., Prichard, M., Wolf, D. G. & Mandelboim, O. (2009). 583 
Analysis of human cytomegalovirus-encoded microRNA activity during infection. J Virol 83, 584 
10684-10693. 585 
Steven, N. M., Leese, A. M., Annels, N. E., Lee, S. P. & Rickinson, A. B. (1996). Epitope focusing in 586 
the primary cytotoxic T cell response to Epstein-Barr virus and its relationship to T cell 587 
memory. J Exp Med 184, 1801-1813. 588 
Tarrant-Elorza, M., Rossetto, C. C. & Pari, G. S. (2014). Maintenance and replication of the human 589 
cytomegalovirus genome during latency. Cell Host Microbe 16, 43-54. 590 
Taylor-Wiedeman, J., Sissons, J. G., Borysiewicz, L. K. & Sinclair, J. H. (1991). Monocytes are a major 591 
site of persistence of human cytomegalovirus in peripheral blood mononuclear cells. J Gen 592 
Virol 72 ( Pt 9), 2059-2064. 593 
Taylor-Wiedeman, J., Sissons, P. & Sinclair, J. (1994). Induction of endogenous human 594 
cytomegalovirus gene expression after differentiation of monocytes from healthy carriers. J 595 
Virol 68, 1597-1604. 596 
Visconti, M. R., Pennington, J., Garner, S. F., Allain, J. P. & Williamson, L. M. (2004). Assessment of 597 
removal of human cytomegalovirus from blood components by leukocyte depletion filters 598 
using real-time quantitative PCR. Blood 103, 1137-1139. 599 
Warming, S., Costantino, N., Court, D. L., Jenkins, N. A. & Copeland, N. G. (2005). Simple and highly 600 
efficient BAC recombineering using galK selection. Nucleic Acids Res 33, e36. 601 
Weekes, M. P., Tan, S. Y., Poole, E., Talbot, S., Antrobus, R., Smith, D. L., Montag, C., Gygi, S. P., 602 
Sinclair, J. H. & Lehner, P. J. (2013). Latency-associated degradation of the MRP1 drug 603 
transporter during latent human cytomegalovirus infection. Science 340, 199-202. 604 
Wills, M. R., Poole, E., Lau, B., Krishna, B. & Sinclair, J. H. (2015). The immunology of human 605 
cytomegalovirus latency: could latent infection be cleared by novel immunotherapeutic 606 
strategies? Cell Mol Immunol 12, 128-138. 607 
Zaia, J. A. (1990). Epidemiology and pathogenesis of cytomegalovirus disease. Semin Hematol 27, 5-608 
10; discussion 28-19. 609 
  610 
Table legends 611 
Table 1. Primer sets for PCR and qPCR used in this study. 612 
Figure legends 613 
 
 
Fig. 1. Removal of the miR-UL112-1 target site leads to induction of IE gene expression in the 614 
absence of virion production. (a) The target site of miR-UL112-1 in the 3’ UTR of IE72 was deleted to 615 
generate a recombinant virus in which IE72 is no longer targeted by miR-UL112-1. (b) Monocytes 616 
(mono) were either uninfected, infected with wild type TB40E (WT) or the miR-UL112-1 target site 617 
mutant virus (∆112-1) and latency was established for 4 days before harvesting and analysing mRNA 618 
levels for viral products UL138, IE and pp28 relative to cellular gene GAPDH. Alternatively, these 619 
gene products were analysed following reactivation from latency by differentiation to dendritic cells 620 
(DC) (reactivation). (c) Both latent monocytes and reactivating DCs, described in (a), were also co-621 
cultured with indicator fibroblasts and supernatants harvested and seeded onto fresh fibroblasts for 622 
24h before fixing and immunofluorescence staining for IE protein, which was used to determined the 623 
IE foci forming units. 624 
Fig. 2. Monocytes latently infected with HCMV ∆112-1 target site mutant are recognized specifically 625 
by IE-specific CD8+ T cells. Monocytes (Mono) were latently infected with either wild-type HCMV 626 
(WT) or miR-UL112-1 target site mutant virus (∆112-1) and a proportion of cells from each 627 
population were also differentiated to dendritic cells (DC) by IL-4 and GM-CSF treatment to induce 628 
reactivation. Both the undifferentiated and differentiated cells were then co-cultured with IE (VLE) 629 
specific CD8 T cells and then assayed for IFNϒ secretion using Fluorospot assays. Mock infected 630 
monocytes (Mono mock) and dendritic cells (DC mock), were also co-cultured with IE (VLE) specific 631 
CD8 T cells. The levels of T cell recognition is shown relative to the level of T cell recognition of 632 
reactivating THP-1 cells (induced to reactivate by PMA). Error bars denote standard deviation of 3 633 
biological replicates. T cells alone showed no background spots and reactivating THP-1 routinely 634 
showed in the region of 4-50 spot forming units. 635 
Fig. 3. Characterization of the THP-1 latency and reactivation model in low serum. (a) THP-1 cells 636 
were infected with TB40/E at MOI 5 and left for 3 days to obtain a latently infected population. PMA 637 
was added on day 3 and left on the cells for 24, 48 or 72 hours; cDNA was produced and amplified 638 
 
 
using IE, UL138 and GAPDH primers. RT minus control samples (no RT) were run in parallel to 639 
exclude genomic DNA contamination. A representative experiment of three independent replicates 640 
is shown. Lane 1: 100bp DNA ladder (Life Technologies); Lane 2: mock infected, untreated; Lane 3: 641 
mock infected, 100nM PMA; Lane 4: TB40/E infected, untreated; Lane 5: TB40/E infected, 100nM 642 
PMA; Lane 6: TB40/E infected, untreated; Lane 7: TB40/E infected, 100nM PMA; Lane 8: TB40/E 643 
infected, untreated; Lane 9: TB40/E infected, 100nM PMA. (b) Microscopic images of TB40/E 644 
infected, undifferentiated THP-1 cells (latency) (left panel) and TB40/E latently infected THP-1 cells, 645 
differentiated on day 3 post infection with 100nM PMA (reactivation) (right panel). (c) Cells from fig. 646 
b, left panel or right panel were co-cultured with fibroblasts for 5 days (left panel or right panel, 647 
respectively). For all panels in (b) and (c), IE expression was visualised using immunofluorescence 648 
staining with anti-IE72/86 antibody. Arrows indicate IE expressing cells. 649 
Fig. 4. Latent infection with Δ112-1 target site mutant virus results in increased levels of IE72 RNA 650 
expression compared to wild-type virus. THP-1 cells were infected at MOI 5 with the parental WT 651 
virus or the Δ112-1 target site mutant. Latently infected cells were sorted for GFP expression at 2 652 
days post infection, before mRNA expression was analysed by RT-qPCR at 3 dpi. The level of UL138 653 
and IE72 normalised to the mRNA level of housekeeping gene GAPDH is shown in (a) and (b), 654 
respectively. 655 
Fig. 5.  IE (VLE) specific CD8+ T cells recognises lytically but not latently infected THP-1 cells. (a) THP-1 656 
cells were stained with monoclonal antibody specific for MHC Class I HLA-A2 (filled plot) or an 657 
isotype matched control antibody (open plot). (b) THP-1 cells were pulsed with IE (VLE) peptide 658 
(pulsed) and assayed with control THP-1 cells (unpulsed) for their ability to be recognised by 659 
increasing numbers of IE (VLE) specific CD8+ T cells; as measured by IFNγ production in ELISPOT 660 
assays. (c) Latently infected THP-1 cells (latent), lytically infected differentiated THP-1 cells (lytic) or 661 
latently infected THP-1 cells differentiated with PMA to induce HCMV reactivation  (reactivated) 662 
were co-cultured with increasing numbers of IE (VLE) specific CD8+ T cells (as detailed in the figure)  663 
 
 
and assayed for IFNϒ  using ELISPOT assay. (d) ∆112-1 target mutant allows recognition and removal 664 
of latently infected cells. THP-1 cells were infected at MOI 5 with the parental WT virus (WT) or the 665 
Δ112-1 target virus before latently infected cells were sorted for GFP expression at 2 days post 666 
infection. At 3 days post infection, the cells were co-cultured with CD8+ T cells as indicated for a 667 
further 24 hours before the numbers of GFP expressing cells were enumerated. Changes in GFP+ cell 668 
numbers are shown as fold change over the number of GFP+ cells present in wild type virus infected 669 
THP-1 cells cultured in the absence of T cells. Statistical analysis was performed using t-test, with * 670 
indicating significant difference (p<0.05). Error bars denote standard deviation of technical 671 
replicates. 672 
673 
 
 
Table 1.  674 
Conventional PCR 
Gene Sequence Reference 
IE Fwd CAT CCA CAT CTC CCG CTT AT (Reeves et al.) 
IE Rev CAC GAC GTT CCT GCA GAC TAT G  
GAPDH Fwd GAG TCA ACG GAT TTG GTC GT  
GAPDH Rev TTG ATT TTG GAG GGA TCT CG  
UL138 Fwd TGC GCA TGT TTC TGA GCT AC (Goodrum et al., 2007) 
UL138 Rev ACG GGT TTC AAC AGA TCG AC  
Probe-based qPCR 
Gene Sequence Reference 
IE72 Fwd CAA GAA CTC AGC CTT CCC TAA GAC (Visconti et al., 2004) 
IE72 Rev TGA GGC AAG TTC TCG AAT GC  
IE72 probe [6FAM] CCA ATG GCT GCA GTC AGG CCA TG [TAM]  
GAPDH Fwd GGA AGC TTG TCA TCA ATG (Poole et al., 2014) 
GAPDH Rev CCC CAC TTG ATT TTG GAG  
GAPDH probe [JOE] ATC ACC ATC TTC CAG GAG CGA G [BHQ1]  
UL138 Fwd CGC TGT TTC TCT GGT TAG (Krishna et al., 2016) 
UL138 Rev CAG ACG ATA CCG TTT CTC  
UL138 probe [Cy5] CCG ACG ACG AAG ACG ATG AAC [BHQ2]  
pp28 Fwd CGA ACT CTG CAA ACG AAT A (Krishna et al., 2016) 
pp28 Rev GAG GGA TGT TGT CGT AGG  
pp28 probe [Cy3] CGT AGA GAC ACC TGG CGA CC [BHQ2]  
 675 
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Supplementary Fig. S1 
A representative image for the genome maintenance over time in reduced and 10% serum 
conditions as determined by end-point PCR. THP-1 cells grown in serum-reduced conditions or in 
10% serum were mock infected (lane 2) or infected at MOI 5 (lanes 3-10). DNA samples were 
prepared 1 day (lane 2 and lane 3), 3 days (lane 4), 6 days (lane 5), 9 days (lane 6), 13 days (lane 7) 
and 20 days post-infection (lane 8). End-point PCR for the viral IE region and the cellular control 
GAPDH was performed on input normalized total DNA. A 100bp ladder (Life Technologies) was used 
to verify the amplicon size (lane 1), as a positive control DNA of infected HFF (lane 10, MOI 5, 3 days 
p.i.) was amplified. A no template control is shown in lane 9. 
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